Newer glucose‐lowering drugs reduce the risk of late‐onset seizure and epilepsy: A meta‐analysis
Abstract Newer glucose‐lowering drugs (GLDs) protect against cerebrovascular, neurodegenerative, and neuroinflammatory pathologies. Therefore, we performed a meta‐analysis of randomized controlled trials (RCTs) comparing newer GLDs to placebo that assessed long‐term cardiovascular and renal outcomes...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | Epilepsia Open |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/epi4.13091 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|